Brendan Kelly
InvestorSenior Director, Healthcare Venture Investments at Leaps by Bayer
Boston, Massachusetts, United States
Find your path to Brendan
810 people in our graph share verified history with Brendan β schools, employers, funds. One of them is your warm intro.
About
Brendan Kelly is Senior Director of Healthcare Venture Investments at Leaps by Bayer. He is a computational medicinal chemist with nine years of research experience across academic and industrial drug discovery teams, including projects with Pfizer and Eli Lilly, and previously conducted postdoctoral research on GPCR signaling in the Stanford University Computer Science Department. He is a founder and board member of A2A Pharmaceuticals, a computational fragment-based drug discovery company focused on oncology and drug-resistant bacterial infections, and has worked as a life sciences consultant and advisor to an early-stage angel investment firm.
ContactΒ· self-published, not guessed
Experience
- Leaps by BayerSenior Director, Healthcare Venture Investmentscurrent2026 β presentCambridge, Massachusetts, United States
- Lightstone VenturesPrincipal2024 β 2026Boston, Massachusetts, United States
- Lightstone VenturesVice President2021 β 2024Boston, Massachusetts, United States
- A2A PharmaceuticalsCo-Founder and Strategic Advisor2016 β 2021
- A2A PharmaceuticalsHead Of Research And Development2017 β 2018
- Q32 Bio Inc.Director, New Product Planning2021Cambridge, Massachusetts, United States
- Q32 Bio Inc.Assoc. Director, New Product Planning2020 β 2021Cambridge, Massachusetts, United States
- OS FundLife Sciences Venture Advisor2017 β 2021Greater Boston
- L.E.K. ConsultingLife Sciences Consultant2020Boston, Massachusetts, United States
- L.E.K. ConsultingSenior Life Science Specialist2019 β 2020Greater Boston
- L.E.K. ConsultingLife Science Specialist2018 β 2019Boston
- Stanford UniversityPostdoctoral Researcher, Computational Drug Discovery2015 β 2017Palo Alto, California
- University Health Network, University of TorontoPostdoctoral Fellow2013 β 2015Toronto, Canada
- Trinity College Dublin, Department of BiochemistryResearcher2012 β 2013Dublin, Ireland
- University of BarcelonaVisiting Researcher2012Greater Barcelona Metropolitan Area
- Trinity College DublinLecturer2009 β 2012Dublin, Ireland
Skills & more
+7 more
ChemistryNMROrganic SynthesisScientific WritingMolecular BiologyLife SciencesLinuxLanguages English Β· French Β· Spanish
From Brendan's professional profile.
Colleagues at Leaps by Bayer
Frequently asked questions
- Who is Brendan Kelly?
- Brendan Kelly is Senior Director of Healthcare Venture Investments at Leaps by Bayer. He is a computational medicinal chemist with nine years of research experience across academic and industrial drug discovery teams, including projects with Pfizer and Eli Lilly, and previously conducted postdoctoral research on GPCR signaling in the Stanford University Computer Science Department. He is a founder and board member of A2A Pharmaceuticals, a computational fragment-based drug discovery company focused on oncology and drug-resistant bacterial infections, and has worked as a life sciences consultant and advisor to an early-stage angel investment firm.
- Where does Brendan Kelly work?
- Brendan Kelly is Senior Director, Healthcare Venture Investments at Leaps by Bayer.
- Where did Brendan Kelly go to school?
- Brendan Kelly studied at Trinity College Dublin (Doctor of Philosophy (Ph.D.), Design, synthesis and evaluation of alpha 2 adrenoceptor antagonists for the treatment of depression); Trinity College Dublin (Bachelor of Science (BSc), Medicinal Chemistry).
Same school
Also attended Trinity College Dublin182
+ 176 more
Shared employers
Also worked at Lightstone Ventures18
+ 12 more
Also worked at A2A Pharmaceuticals2
Also worked at OS Fund3
Also worked at L.E.K. Consulting185
+ 179 more



























.jpg)




